FIELD: medicine.
SUBSTANCE: invention relates to medicine and biotechnology and can be used for analgesia. Plasmid DNA for transient expression in cells of mammals is represented by scaffold, containing prokaryotic elements, origin of replication and reporter gene, and eukaryotic elements, strong promoter, a leader sequence mRNA, as well as regulatory sequences for the specified elements, from one site for cloning of a gene of interest and from one site for landing from one primer for analysis of composition of plasmid DNA, and polynucleotide presented by secretory sequence, the fragment coding human's alpha defensin HNP-1, or HNP-2, or HNP-3, kodonnally optimized for expression in mammalian cells, and the terminating sequence. Also a producer of plasmid DNA and analgesic agent based on it are disclosed.
EFFECT: using inventions allows to extend the range of analgesic agents, to increase the duration and safety of analgesia.
5 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN, DNA, GENETIC CONSTRUCT, RECOMBINANT CELL, FUSION PROTEIN-BASED VACCINE FOR TUBERCULOSIS PREVENTION AND TREATMENT (VERSIONS) | 2015 |
|
RU2615440C2 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION BASED ON A GENETIC CONSTRUCT | 2020 |
|
RU2747762C1 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC FOR LEGUMAIN | 2013 |
|
RU2574203C2 |
| METHOD FOR OBTAINING RECOMBINANT HUMAN OREXIN A , PLASMID DNA, STRAIN PRODUCER | 2016 |
|
RU2647771C2 |
| HYBRID PROTEIN IGF-1-LONG FOR TREATING STROKE, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2018 |
|
RU2711111C1 |
| VARIABLE DOMAINS OF LIGHT AND HEAVY CHAINS OF MURINE MONOCLONAL ANTIBODIES AGAINST HUMAN ALPHA-DEFENSINS 1-3 (HNP 1-3), ANTIGEN-BINDING FRAGMENTS (FAB) AGAINST HUMAN HNP 1-3, CONTAINING SAID DOMAINS | 2019 |
|
RU2724733C1 |
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
